drugset
drugset / Trial / NCT01366651

A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age

NCT01366651 ↗

Phase 1 Terminated 1 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-label

Summary

The purpose of this study is to characterize the penetration of doripenem in the cerebral spinal fluid in pediatric patients \<1 year of age who are hospitalized and have a documented or suspected infection and are planning to, or undergoing treatment with intravenous (IV) antibiotics.

Timeline

Start
2012-03
Primary completion
2012-05
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Doripenem Small molecule 10 mg/kg Intravenous
Subject Doripenem Small molecule 30 mg/kg Intravenous

Indications

meningitis